Advanced search
Showing result 11 - 15 of 38 swedish dissertations matching the above criteria.
-
11. The use of molecular techniques for identification of genetic divergence in transplantation : with special reference to MHC genes and HLA typing
Abstract : Transplantation immunology basically deals with the immune mechanisms that lead to rejection of transplanted tissues. Lymphocytes are the key mediators of graft rejection. At the time for this observation, the genetic loci responsible for histocompatibility between individuals of the same species were already identified in the mouse. READ MORE
-
12. Neuroblastoma incidence, biology and outcome : with special emphasis on quantitative analysis of tyrosine hydroxylase mRNA in blood and bone marrow
Abstract : Neuroblastoma, the most common malignant disease of early childhood, accounts for 6% of childhood malignancies but is responsible for 9% of paediatric cancer related deaths. The tumour originates from cells in the neural crest and has a very heterogeneous clinical course. READ MORE
-
13. Ultrasensitive Molecular Monitoring of Breast Cancer and Acute Myeloid Leukemia
Abstract : Cancer is the common name to a group of biologically diverse malignant neoplastic diseases. Approximately 18 million people are diagnosed with cancer annually and 8.8 million patients die from it. Tumorigenesis and progression of cancer are driven by alterations in the cancer cell genome. READ MORE
-
14. The role of cannabinoid receptors, G alpha z, and B cell receptor in lymphoma pathobiology with focus on chemotaxis
Abstract : Mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia (CLL) are two incurable B cell malignancies, with an overall survival of 5 to 8 years and 6 to 10 years, respectively. Therapies are available but are often very aggressive, and patients relapse due to minimal residual disease. READ MORE
-
15. Molecular Monitoring of Chronic Myeloid Leukemia Treated with Imatinib Mesylate
Abstract : The BCR-ABL fusion gene product is a constitutively activated tyrosine kinase, which is fundamental in the pathogenesis of chronic myeloid leukemia (CML). Imatinib mesylate (imatinib, Glivec® or Gleevec®), a small molecule inhibitor of the BCR-ABL tyrosine kinase, is now the first-line treatment for all newly diagnosed chronic phase CML patients. READ MORE